Solriamfetol (Sunosi)
What studies of Solriamfetol (Sunosi) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, the placebo trial (very low certainty): 2 of 4 findings are C, a tie, so the grade of cognition (brain fog), as the rule below says.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Solriamfetol (Sunosi) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Solriamfetol (Sunosi) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Cognition (brain fog)1 study · 18 people took Solriamfetol (Sunosi) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (38 in all).
The placebo trial38 randomised · 8 weeks · 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
Cognition (brain fog) improved more than in the comparison group.
The evidence is very uncertain about the effect of solriamfetol (Sunosi) on cognition (brain fog) in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (38 in all)
See the 1 study
-
Same trial, also reported in: Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment (2025) (BRIEF-A: GEC)
- People in the study
- 38 randomised
- Dose
- 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
- Outcome
- BRIEF-A: GEC Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- High
Fatigue1 study · 18 people took Solriamfetol (Sunosi) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 38 people found no clear difference; a small benefit can't be ruled out.
The placebo trial38 randomised · 8 weeks · 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
No clear difference in fatigue.
The evidence is very uncertain about the effect of solriamfetol (Sunosi) on fatigue in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 38 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Same trial, also reported in: Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment (2025) (FSI: Severity)
- People in the study
- 38 randomised
- Dose
- 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
- Outcome
- FSI: Severity Fatigue Symptom Inventory (FSI)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily life and health overall
Overall symptoms1 study · 18 people took Solriamfetol (Sunosi) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (38 in all).
The placebo trial38 randomised · 8 weeks · 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of solriamfetol (Sunosi) on overall symptoms in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (38 in all)
See the 1 study
-
Same trial, also reported in: Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment (2025) (CGI)
- People in the study
- 38 randomised
- Dose
- 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food
- Outcome
- PGI-S Patient Global Impression-Severity (PGI-S)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily functioning1 study · 18 people took Solriamfetol (Sunosi) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 38 people found no clear difference; a small benefit can't be ruled out.
The placebo trial38 started · 8 weeks · 75mg (titrated to 150mg as needed), at the same time each morning upon waking
No clear difference in daily functioning.
The evidence is very uncertain about the effect of solriamfetol (Sunosi) on daily functioning in ME/CFS. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 38 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 38 started
- Dose
- 75mg (titrated to 150mg as needed), at the same time each morning upon waking
- Outcome
- FSI: Interference Fatigue Symptom Inventory
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects2 studies
Two participants in the placebo group withdrew due to AEs; both reported sleep loss and one also experienced headaches, dizziness, and anxiety
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment. (2025)Two participants in the placebo group withdrew due to AEs; both reported sleep loss and one also experienced headaches, dizziness, and anxiety
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment (2025)
Side effects studies reported4 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Dizziness | 1 study |
| Headache | 1 study |
| Trouble sleeping | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
75 mg at the start
- 2Raise
Raised step by step in 2 of 2 studies
- 3Top dose
Most often 150 mg (2 of 2 studies)
Doses across 2 studies
75 to 150 mg.
Each study’s dose, as printed
- 75 mg (titrated to 150 mg as needed), 1 whole capsule at the same time each morning upon waking, with or without food Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment. (2025)
- 75mg (titrated to 150mg as needed), at the same time each morning upon waking Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment (2025)
All papers
- Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.2025 · placebo trial · 38 randomised
Summary
This phase 4, double-blind, randomized, placebo-controlled trial enrolled 38 adults aged 18 to 65 with ME/CFS at a single center. Participants were randomly assigned to solriamfetol 75 mg, titrated to 150 mg as needed, or placebo, for 8 weeks of double-blind treatment, with a follow-up 1 week after Week 8. The primary outcome was the Fatigue Symptom Inventory (FSI); the secondary outcome was the Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A), assessed at Week 6 and Week 8. At Week 8, the text reports a 2.02-point FSI severity improvement with solriamfetol versus 0.46 points with placebo (p = 0.039; Table 3 gives p = 0.042). FSI severity did not differ at Week 6. BRIEF-A global executive composite improved more with solriamfetol at Week 8, driven by the metacognition index at Week 6 and Week 8; behavior regulation index, FSI interference, CGI-S, and FIQ did not differ. PGI-S improved with solriamfetol at Week 6 and Week 8. Adverse events: the text reports 14 (36.8%) participants with at least one AE, while Table 4 reports 7 in the solriamfetol arm and 6 in the placebo arm; total AEs were 13 with solriamfetol and 16 with placebo. Common AEs included sleep loss and headaches. Two placebo participants and one solriamfetol participant withdrew due to AEs; one solriamfetol participant withdrew for travel. The authors state limitations include a small, homogeneous sample, single-center design, baseline variability, a 150 mg maximum dose, and Week 6 telehealth visits.
- Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after eight weeks of treatment2025 · placebo trial · 38 started
Summary
This phase 4, double-blind, randomized, placebo-controlled trial enrolled adults aged 18-65 years who met the Institute of Medicine 2015 diagnostic criteria for ME/CFS. 47 participants were screened; the final sample consisted of 38 participants, with 18 receiving at least one dose of solriamfetol and 20 receiving placebo. Participants started 75mg solriamfetol (titrated to 150mg as needed) or matching placebo and completed 8 weeks of double-blind treatment. The primary outcome was Fatigue Symptom Inventory (FSI) score at weeks 6 and 8; the secondary outcome was Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A). At week 8, participants assigned solriamfetol exhibited a 2.02-point improvement on FSI severity compared with a 0.46-point improvement with placebo (p = .039), but there was no difference at week 6 (p = .270). BRIEF-A global executive composite improved more with solriamfetol at week 8 (p = .012), driven by the metacognition index (p = .004); the behavior regulation index did not differ (p = .574). FSI interference did not improve compared with placebo. PGI-S improved with solriamfetol at weeks 6 and 8, but CGI, CGI-S, and FIQ did not differ; the Sheehan Disability Scale was not analyzable. In total, 14 (36.8%) patients reported at least one adverse event. One participant in the solriamfetol group and two in the placebo group withdrew due to adverse events. Sleep loss was the most common adverse event with solriamfetol (6 instances, 3 patients); anxiety affected 4 patients (4 instances). Headaches were the most common with placebo (8 instances, 4 patients).